A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)
CRISPR Therapeutics
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
A Study of CTX460 in Adults with Emphysema Associated with Severe Alpha-1 Antitrypsin Deficiency (AATD).
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- NOT_YET_RECRUITING
- phase
- PHASE1, PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 68
- sponsor
- CRISPR Therapeutics
- conditions
- Alpha-1 Antitrypsin Deficiency (AATD)
- interventions
- DRUG: CTX460
- start date
- 2026-10-31
- start date type
- ESTIMATED
- primary completion date
- 2030-06-30
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07850076
- Published
- Sep 30, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07850076
- Categories
- Alpha-1 Antitrypsin Deficiency (AATD)
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials